Sugar compound aimed at saving tiny guts: trial pulled before start

NCT ID NCT06547424

Terminated Disease control Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test whether a supplement called chondroitin sulfate is safe for newborns with necrotizing enterocolitis (NEC), a severe gut infection. The plan was to give the supplement to very low birth weight babies for two days and compare their outcomes to those receiving a placebo. However, the trial was withdrawn before any babies were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chondroitin sulfate
What this could lead to: If successful, this could point toward a safe way to reduce surgery and improve outcomes in babies with NEC.
What could go wrong: The trial was withdrawn before any patients were enrolled, so no data exists. It is a very early phase 1 safety study, and benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTESTINAL ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute intestinal ischemia ischemic bowel disorder necrotizing enterocolitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTESTINAL ISCHEMIA NECROTIZING ENTEROCOLITIS

Contacts and locations

Locations

Riley Hospital for Children

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.